Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma

To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrect...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2003-05, Vol.61 (5), p.1072-1077
Main Authors: Miyajima, Akira, Asano, Tomohiko, Seta, Kaori, Asano, Takako, Kakoi, Narihiko, Hayakawa, Masamichi
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Apoptosis - physiology
Biological and medical sciences
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - surgery
DNA Fragmentation - physiology
Female
Gene Expression Regulation, Neoplastic - genetics
Humans
Immunohistochemistry
Kidney Neoplasms - diagnosis
Kidney Neoplasms - genetics
Kidney Neoplasms - surgery
Kidneys
Male
Medical sciences
Middle Aged
Neoplasm Staging - methods
Nephrectomy - methods
Nephrology. Urinary tract diseases
Paraffin Embedding
Prognosis
Proportional Hazards Models
Receptors, Transforming Growth Factor beta - biosynthesis
Receptors, Transforming Growth Factor beta - genetics
Receptors, Transforming Growth Factor beta - immunology
Survival Rate
Tumors of the urinary system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the clinical implication of the loss of transforming growth factor-beta (TGF-β) receptor (TβR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who underwent radical nephrectomy for RCC. Loss of expression in TβR could result in escape from the growth inhibitory effect of TGF-β in TGF-β-secreting cancer. TβR and apoptosis in the tumor were detected by immunohistochemistry using samples from 62 patients. We statistically investigated the relationship among the TβR expression pattern, pathologic features, and the prognosis of patients with RCC. A loss of expression of TβR-I and TβR-II was identified in 29 patients (46.7%) and 31 patients (50.0%), respectively. Although the loss of TβR-I was not associated with clinical stage, the loss of TβR-II was associated with clinical stage ( P
ISSN:0090-4295
1527-9995
DOI:10.1016/S0090-4295(02)02553-0